DRUG WARNING: ETRAVIRINE (INTELENCE)

By /

On October 15, 2009, Tibotec, a division of Janssen-Ortho Inc., in collaboration with Health Canada, issued a Dear Healthcare Professional letter to relay important safety information for Intelence (etravirine).  The letter strengthens warnings and precautions for severe skin reactions to reflect post-marketing reports of:

  • a fatality due to toxic epidermal necrolysis
  • hypersensitivity reactions, sometimes accompanied by hepatic failure

Intelence should be discontinued immediately if signs or symptoms of severe skin rash or hypersensitivity reactions occur.  Clinical status and liver transaminases should be monitored and treated appropriately.  Delays in discontinuing Intelence treatment after the appearance of a severe rash or hypersensitivity reaction may lead to a life-threatening reaction.

For more information: Click here to download the Warning letter issued by Tibotec

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search